Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Romain Coriat

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4420-8340; OpenAlex author ID A5090375155. Sources: OpenAlex.

Their work

Papers
26 (first author 3, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
77
Papers, trials and grants by year

2015: 4 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: 4 papers · 2020: 1 paper · 2021: 6 papers · 2022: 3 papers · 2023: 3 papers · 2024: none · 2025: 2 papers · 2026: 2 papers

Papers 26

  1. Differentiating Between Pancreatic Adenosquamous Carcinoma and Pancreatic Ductal Adenocarcinoma Using Computed Tomography. Co-author DOI 10.1177/08465371261426959↗
  2. Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study Co-author DOI 10.64898/2026.06.18.26355998↗
  3. Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study. Co-author DOI 10.1093/oncolo/oyaf125↗
  4. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  5. Imaging of Pancreatic Ductal Adenocarcinoma: An Update on Recent Advances. Co-author DOI 10.1177/08465371221124927↗
  6. Interobserver Variability and Accuracy of Preoperative CT and MRI in Pancreatic Ductal Adenocarcinoma Size Estimation: A Retrospective Cohort Study. Co-author DOI 10.1177/08465371221137885↗
  7. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  8. Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma? Last author DOI 10.1016/j.esmoop.2022.100638↗
  9. Levels of Evidence Supporting United States Guidelines in Pancreatic Adenocarcinoma Treatment. Co-author DOI 10.3390/cancers14164062↗
  10. Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy. Last author DOI 10.3390/cancers14246179↗
  11. Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. Co-author DOI 10.1016/j.clinre.2020.101607↗
  12. CT features of lung metastases from pancreatic adenocarcinoma: Correlation with histopathologic findings. Co-author DOI 10.1016/j.diii.2020.11.015↗
  13. Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2021.05.006↗
  14. Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. Co-author DOI 10.1038/s41416-021-01341-w↗
  15. Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives. Last author DOI 10.1177/17588359211018539↗
  16. Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13133103↗
  17. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma… Co-author DOI 10.1016/j.ejca.2020.05.018↗
  18. 18F-FDG PET/CT in pancreatic adenocarcinoma: On the edge of a paradigm shift? First author DOI 10.1016/j.diii.2019.11.001↗
  19. Pancreatic cancer surgical management. First author DOI 10.1016/j.lpm.2019.02.027↗
  20. McCune Albright syndrome is a genetic predisposition to intraductal papillary and mucinous neoplasms of the pancreas associated pancreatic cancer in relation w… Co-author DOI 10.1097/md.0000000000018102↗
  21. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRE… Co-author DOI 10.1245/s10434-018-6931-6↗
  22. Care pathway of patients with metastatic pancreatic cancer in daily practice in France: Results from the REPERE national survey. First author DOI 10.1016/j.bulcan.2016.11.022↗
  23. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Co-author DOI 10.1038/bjc.2015.328↗
  24. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Co-author DOI 10.1245/s10434-014-3898-9↗
  25. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-… Co-author DOI 10.1245/s10434-015-4783-x↗
  26. Resection of Late Pulmonary Metastases from Pancreatic Adenocarcinoma: Is Surgery an Option? Last author DOI 10.3109/07357907.2015.1080831↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anna Pellat · 5 shared papers, 2022–2026 · strength 1.03
  2. Maxime Barat · 5 shared papers, 2021–2026 · strength 0.89
  3. Philippe A. Soyer · 5 shared papers, 2021–2026 · strength 0.89
  4. Ugo Marchèse · 5 shared papers, 2021–2026 · strength 0.89
  5. Pascal R. Hammel · 6 shared papers, 2015–2026 · strength 0.73
  6. Jean‐Baptiste Bachet · 7 shared papers, 2015–2026 · strength 0.67
  7. Isabelle Trouilloud · 5 shared papers, 2015–2026 · strength 0.57
  8. Julien Taı̈eb · 6 shared papers, 2015–2025 · strength 0.45
  9. Christelle de la Fouchardière · 4 shared papers, 2015–2026 · strength 0.40
  10. Lysiane Marthey · 5 shared papers, 2015–2025 · strength 0.38
  11. António Sá Cunha · 5 shared papers, 2015–2021 · strength 0.36
  12. Lola‐Jade Palmieri · 2 shared papers, 2019–2021 · strength 0.36
  13. David Tougeron · 3 shared papers, 2015–2025 · strength 0.30
  14. Franck Bonnetain · 3 shared papers, 2015–2025 · strength 0.28
  15. Marwa Alkatheeri · 1 shared paper, 2026 · strength 0.27
  16. Thị Thùy Linh Nguyễn · 1 shared paper, 2026 · strength 0.27
  17. Émilie Soularue · 2 shared papers, 2021–2025 · strength 0.27
  18. Raëf Abdallah · 2 shared papers, 2021–2025 · strength 0.26
  19. Nicolas Williet · 2 shared papers, 2021–2025 · strength 0.26
  20. Olivia Hentic · 3 shared papers, 2015–2021 · strength 0.24
  21. Philippe Ravaud · 1 shared paper, 2022 · strength 0.22
  22. Yves Rinaldi · 1 shared paper, 2026 · strength 0.22
  23. Déwi Vernerey · 1 shared paper, 2026 · strength 0.22
  24. Cindy Neuzillet · 1 shared paper, 2026 · strength 0.22
  25. Benoı̂t Rousseau · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.